
Over the past decade, conduction system pacing (CSP) has been an emerging and more commonly used technique in the field of cardiac pacing. Conduction system pacing involves implantation of a permanent pacing lead along the cardiac conduction system and is done either through His-bundle pacing (HBP) or left bundle branch area pacing (LBBAP). Unlike traditional biventricular pacing (BVP), CSP allows for a more physiological way to pace the heart, with observational studies showing equal or even better improvements in QRS duration and LV function, and possibly greater hemodynamic benefits1. Despite these potential benefits, randomized clinical trials comparing hard clinical outcomes for CSP versus biventricular pacing are still lacking.
Two studies1,2, by Dr. Vijayaraman and his colleagues, recently published in Heart Rhythm, further assessed the impact of CSP on clinical outcomes and add to the growing evidence supporting CSP as a possible alternative to biventricular pacing for cardiac resynchronization therapy (CRT).
he first study reviewed retrospective data from two US centers including 477 adult patients (32% women) with an LV ejection fraction of < 35% and who had an indication for cardiac resynchronization therapy, of which 258 underwent successful CSP and 219 underwent biventricular pacing. In a mean follow-up period of 27 +12 months, the primary outcome of all-cause death or heart failure hospitalization was significantly lower with CSP versus BVP (28.3% vs 38.3%, HR 1.52; 95% CI 1.08-2.09; P = 0.013). This was primarily driven by significantly lower heart failure hospitalizations (15% vs 34%, HR 3.15, 95% CI 2.07-4.79, P <0.001) in the CSP group.